SeaStar Medical earns FDA Breakthrough Device Designation for Selective Cytopheretic Device in cardiorenal syndrome

  • Kevin Chung

Press/Media

Period29 Sep 2023

Media coverage

4

Media coverage

  • TitleSeaStar Medical earns FDA Breakthrough Device Designation for Selective Cytopheretic Device in cardiorenal syndrome
    Media name/outletM2 Pharma
    Country/TerritoryUnited States
    Date29/09/23
    PersonsKevin Chung
  • TitleSeaStar Medical earns FDA Breakthrough Device Designation for Selective Cytopheretic Device in cardiorenal syndrome
    Media name/outletFinancialWire
    Country/TerritoryAustralia
    Date29/09/23
    PersonsKevin Chung
  • TitleSeaStar Medical earns FDA Breakthrough Device Designation for Selective Cytopheretic Device in cardiorenal syndrome
    Media name/outletM2Pharma.com
    Country/TerritoryUnited States
    Date29/09/23
    URLct.moreover.com/?a=51933275924&p=1gw&v=1&x=JCcInLKgktJcmMX4l2_njg
    PersonsKevin Chung
  • TitleSeaStar Medical earns FDA Breakthrough Device Designation for Selective Cytopheretic Device in cardiorenal syndrome
    Media name/outletM2 EquityBites
    Country/TerritoryUnited Kingdom
    Date29/09/23
    PersonsKevin Chung